Nkarta to Participate in Upcoming Investor Conference
04 9월 2024 - 5:01AM
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing
engineered natural killer (NK) cell therapies, today announced its
participation in the following investor conference:
H.C. Wainwright
26th Annual Global Investment
ConferenceSeptember 10, 202412:30 p.m. ET – fireside
chat
A simultaneous webcast of each event will be available on the
Investors section of Nkarta’s website, www.nkartatx.com, and a
replay will be archived on the website for approximately 90
days.
About NkartaNkarta is a clinical-stage
biotechnology company advancing the development of allogeneic,
off-the-shelf natural killer (NK) cell therapies. By combining its
cell expansion and cryopreservation platform with proprietary cell
engineering technologies and CRISPR-based genome engineering
capabilities, Nkarta is building a pipeline of future cell
therapies engineered for deep therapeutic activity and intended for
broad access in the outpatient treatment setting. For more
information, please visit the company’s website at
www.nkartatx.com.
Nkarta Media/Investor Contact:Greg MannNkarta,
Inc.gmann@nkartatx.com
Nkarta (NASDAQ:NKTX)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Nkarta (NASDAQ:NKTX)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024